Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World

BACKGROUND: Osimertinib is considered the standard-of-care for previously-untreated EGFR mutant advanced non-small cell lung cancer (NSCLC). Oncogene driver screening in early NSCLC is not standard practice. A real-world study has been designed in order to investigate the optimal testing frequency a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasello, Giulia, Lorenzi, Martina, Pretelli, Giulia, Comacchio, Giovanni Maria, Pezzuto, Federica, Schiavon, Marco, Buja, Alessandra, Frega, Stefano, Bonanno, Laura, Guarneri, Valentina, Calabrese, Fiorella, Rea, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278847/
https://www.ncbi.nlm.nih.gov/pubmed/35847912
http://dx.doi.org/10.3389/fonc.2022.909064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278847/
https://www.ncbi.nlm.nih.gov/pubmed/35847912
http://dx.doi.org/10.3389/fonc.2022.909064

Ejemplares similares